2-chloro-5-(4-(trifluoromethyl)phenyl)oxazole | 1238893-96-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloro-5-(4-(trifluoromethyl)phenyl)oxazole
• 英文别名: Oxazole, 2-chloro-5-[4-(trifluoromethyl)phenyl]-；2-chloro-5-[4-(trifluoromethyl)phenyl]-1,3-oxazole
• CAS: 1238893-96-3
• 化学式: C₁₀H₅ClF₃NO
• 分子量: 247.604
• InChiKey: ZHDYCOZXSGWVIR-UHFFFAOYSA-N

物化性质

• 沸点：
  297.8±50.0 °C(Predicted)
• 密度：
  1.405±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(4-(trifluoromethyl)phenyl)oxazole 、 3-氨基苯酚 在 silica 、 acetone hexane 作用下， 以 异丙醇 为溶剂， 反应 14.0h， 以to provide 3-((5-(4-(trifluoromethyl)phenyl)oxazol-2-yl)amino)phenol 32 (0.26 g, 40% yield) as a solid的产率得到3-((5-(4-(trifluoromethyl)phenyl)oxazol-2-yl)amino)phenol
  参考文献：
  名称：

  Aminooxazole inhibitors of cyclin dependent kinases

  摘要：

  本文描述了噁唑衍生物。这些创新化合物可用作激酶抑制剂，并可用于治疗癌症，如前列腺癌，肺癌，乳腺癌，结肠癌，白血病，中枢神经系统癌症，黑色素瘤，卵巢癌和肾癌。

  公开号：

  US08551992B2
• 作为产物：
  描述：

  5-[4-(三氟甲基)苯基]-1,3-恶唑 在 lithium hexamethyldisilazane 、 六氯乙烷 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以97%的产率得到2-chloro-5-(4-(trifluoromethyl)phenyl)oxazole
  参考文献：
  名称：

  Aminooxazole Inhibitors of Cyclin Dependent Kinases

  摘要：

  噁唑衍生物被描述。这些创新化合物可用作激酶抑制剂，并可用于治疗癌症，如前列腺癌、肺癌、乳腺癌、结肠癌、白血病、中枢神经系统癌症、黑色素瘤、卵巢癌和肾癌。

  公开号：

  US20120302578A1

文献信息

• [EN] DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE DIAMINOCYCLOHEXANE ET LEURS UTILISATIONS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013012827A1

  公开（公告）日：2013-01-24

  The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

  本发明提供了化合物的结构式（I），或其立体异构体，或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是NPY Y4受体的激动剂、部分激动剂和调节剂，可用于治疗和预防各种疾病和病况。
• DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF
  申请人：Ewing William R.

  公开号：US20130184284A1

  公开（公告）日：2013-07-18

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

  本发明提供式(I)化合物：或其立体异构体或药学上可接受的盐，其中所有变量的定义如本文所述。这些化合物是 NPY Y4 受体的激动剂、部分激动剂和调节剂，可用于治疗和预防各种疾病和病况。
• 1,3-Oxazole-4-carboxamides, 1,3-Thiazole-4-carboxamides, and 1,3-Imidazole-d-carboxamides as Inhibitors of cyclin Dependent kinases
  申请人：Neosome Life Sciences, LLC

  公开号：US08546400B2

  公开（公告）日：2013-10-01

  Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and renal cancer.

  本文描述了噁唑衍生物。这些创新化合物可用作激酶抑制剂，可用于治疗癌症，如前列腺癌，肺癌，乳腺癌，结肠癌，白血病，中枢神经系统癌症，黑色素瘤，卵巢癌和肾癌。
• WO2021012018A5
  申请人：——

  公开号：WO2021012018A5

  公开（公告）日：2023-07-31
• Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists
  作者：Richard J. Perner、John R. Koenig、Stanley DiDomenico、Arthur Gomtsyan、Robert G. Schmidt、Chih-Hung Lee、Margaret C. Hsu、Heath A. McDonald、Donna M. Gauvin、Shailen Joshi、Teresa M. Turner、Regina M. Reilly、Philip R. Kym、Michael E. Kort

  DOI：10.1016/j.bmc.2010.04.099

  日期：2010.7

  The synthesis and structure-activity relationships of a series of 5-monosubstituted and 4,5-disubstituted 2-arylaminooxazoles as novel antagonists of the transient receptor potential vanilloid 1 (TRPV1) receptor are described. The 7-hydroxy group of the tetrahydronaphthyl moiety on the 2-amino substituent of the oxazole ring was important for obtaining excellent in vitro potency at the human TRPV1 receptor, while a variety of alkyl and phenyl substituents at the 4- and 5-positions of the oxazole ring were well tolerated and yielded potent TRPV1 antagonists. Despite excellent in vitro potency, the 5-monosubstituted compounds suffered from poor pharmacokinetics. It was found that 4,5-disubstitution on the oxazole ring was critical to the improvement of the overall pharmacokinetic profile of these analogues, which led to the discovery of compound (R)-27, a novel TRPV1 antagonist with good oral activity in preclinical animal models of pain. (C) 2010 Elsevier Ltd. All rights reserved.